Melanie J Davies Selected Research

Glucagon-Like Peptide-1 Receptor Agonists

1/2022	Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.
1/2021	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.
6/2020	Cardiovascular outcome trials of glucose-lowering therapies.
1/2020	Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
1/2020	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
1/2020	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
1/2020	Emerging glucose-lowering therapies: a guide for cardiologists.
11/2019	The right place for Sulphonylureas today.
11/2018	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol.
1/2018	What have we learnt from "real world" data, observational studies and meta-analyses.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Melanie J Davies Research Topics

Disease

92	Type 2 Diabetes Mellitus (MODY) 07/2022 - 09/2003
18	Body Weight (Weight, Body) 03/2022 - 12/2011
15	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 04/2010
14	Obesity 01/2022 - 01/2011
12	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 10/2007
11	Glucose Intolerance 05/2020 - 01/2002
10	Weight Loss (Weight Reduction) 01/2022 - 11/2012
10	Insulin Resistance 01/2022 - 01/2012
10	Heart Failure 01/2022 - 04/2010
10	Weight Gain 11/2019 - 01/2002
7	Myocardial Infarction 01/2022 - 04/2010
7	Stroke (Strokes) 01/2022 - 04/2010
7	Chronic Renal Insufficiency 01/2021 - 01/2013
6	Overweight 01/2022 - 01/2015
4	COVID-19 01/2022 - 01/2021
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 07/2006
4	Nausea 01/2021 - 01/2016
4	Chronic Disease (Chronic Diseases) 01/2021 - 12/2019
4	Neoplasms (Cancer) 10/2020 - 04/2019
4	Prediabetic State (Prediabetes) 07/2017 - 10/2010
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2014 - 04/2010
3	Hyperglycemia 01/2022 - 10/2009
3	Vomiting 01/2021 - 01/2017
3	Unstable Angina 04/2019 - 04/2010
2	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2022 - 01/2021
2	Infections 01/2022 - 01/2015
2	Cardiac Arrhythmias (Arrythmia) 01/2022 - 08/2015
2	Peripheral Nervous System Diseases (PNS Diseases) 12/2019 - 07/2014
2	Venous Thromboembolism 10/2019 - 01/2018
2	Inflammation (Inflammations) 01/2019 - 01/2012
1	Heart Arrest (Cardiac Arrest) 01/2022
1	Ischemia 01/2022
1	Necrosis 01/2021

Drug/Important Bio-Agent (IBA)

59	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 07/2006
34	Insulin (Novolin)FDA Link 01/2022 - 01/2002
14	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2015
11	Metformin (Glucophage)FDA LinkGeneric 01/2021 - 01/2002
11	Liraglutide FDA Link 01/2021 - 07/2011
9	LipidsIBA 03/2022 - 01/2011
9	Insulin Glargine (Lantus)FDA Link 01/2022 - 07/2006
9	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2018
8	Biomarkers (Surrogate Marker)IBA 03/2022 - 12/2011
8	SodiumIBA 01/2022 - 01/2015
8	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2012
7	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2012
7	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 11/2012
7	CholesterolIBA 10/2020 - 04/2010
6	Sodium-Glucose Transport ProteinsIBA 01/2022 - 12/2017
5	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 10/2007
5	Glucagon-Like Peptide-1 ReceptorIBA 01/2021 - 01/2015
5	Sitagliptin Phosphate (Januvia)FDA Link 01/2021 - 01/2020
4	IncretinsIBA 01/2020 - 07/2011
4	Pharmaceutical PreparationsIBA 01/2020 - 04/2014
4	HDL CholesterolIBA 08/2019 - 01/2012
4	Hypoglycemic Agents (Hypoglycemics)IBA 08/2015 - 10/2007
3	empagliflozinIBA 01/2022 - 01/2020
3	lixisenatideIBA 01/2022 - 12/2017
3	omega-Chloroacetophenone (Mace)IBA 01/2020 - 03/2019
3	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2020 - 11/2015
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 01/2018
3	AlbuminsIBA 01/2020 - 12/2018
3	CreatinineIBA 01/2020 - 07/2017
3	dulaglutideIBA 10/2019 - 01/2016
3	Exenatide (Byetta)FDA Link 01/2017 - 01/2015
3	Nateglinide (Starlix)FDA LinkGeneric 08/2015 - 04/2010
3	Valsartan (Vals)FDA Link 08/2015 - 04/2010
2	Peptides (Polypeptides)IBA 01/2022 - 01/2021
2	trimethyloxamine (trimethylamine N-oxide)IBA 01/2021 - 12/2020
2	semaglutideIBA 01/2021 - 10/2019
2	Nonesterified Fatty Acids (NEFA)IBA 01/2021 - 01/2016
2	ORALIT (ORS)IBA 01/2021 - 12/2014
2	C-Reactive ProteinIBA 01/2021 - 08/2015
2	2,4-thiazolidinedione (thiazolidinedione)IBA 01/2020 - 08/2015
2	SymportersIBA 01/2020 - 01/2015
2	Insulin SecretagoguesIBA 11/2019 - 01/2002
2	SmokeIBA 08/2019 - 10/2015
2	InsulinsIBA 02/2019 - 08/2008
2	ThiazolidinedionesIBA 01/2018 - 09/2003
2	Short-Acting InsulinIBA 01/2018 - 04/2010
2	rGLP-1 proteinIBA 01/2017 - 01/2016
2	Long-Acting Insulin (Insulin, Long Acting)FDA Link 11/2015 - 08/2008
2	Insulin Detemir (Levemir)FDA Link 08/2008 - 10/2007
1	SolutionsIBA 01/2022
1	Hormones (Hormone)IBA 01/2022
1	VaccinesIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	tirzepatideIBA 01/2021
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021
1	Prostaglandins DIBA 01/2021
1	Adenosine (Adenocard)FDA LinkGeneric 01/2021
1	Advanced Glycation End ProductsIBA 01/2021
1	MicronutrientsIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021

Therapy/Procedure

32	Therapeutics 01/2022 - 09/2003
11	Glycemic Control 01/2021 - 10/2007
3	Injections 01/2022 - 07/2006
2	Walkers 01/2021 - 12/2019
2	Critical Care (Surgical Intensive Care) 01/2021 - 12/2018
1	Secondary Prevention 07/2022
1	Caloric Restriction 01/2022